Varios

Genome-wide studies in pharmacogenomics harnessing the power of extreme phenotypes

SLC2A4 gene-a promising target for pharmacogenomics of insulin resistance

Can pharmacogenomics improve malaria drug policy

Biomarkers to optimize the treatment of nicotine dependence

Development of biomarkers to optimize pediatric patient management-what makes children different

Rare versus common variants in pharmacogenetics - SLCO1B1 variation and methotrexate disposition

Association of Factor V Leiden gene polymorphism with arteriovenous graft failure

Just how feasible is pharmacogenetic testing in the primary healthcare setting

PharmaGKB summary - phenytoin pathway

Significance of genetic polymorphism of CYP2D6 in the pathohgenesis of systemic sclerosis

Lessons from pharmacogenetics and metoclopramide

Genome-wide approaches in pharmacogenomics

Pharmacogenetic study of drug-metabolising enzyme polymorphisms

Farmacogenómica de los AINEs- personalizar el tratamiento

Genetic loci associated delayed clearance P falciparum following artemisinin treatment

Delamanid for multidrug-resistant pulmonary tuberculosis

Regresar al Acervo